10x Genomics (NASDAQ:TXG) Issues Earnings Results, Beats Expectations By $0.12 EPS

10x Genomics (NASDAQ:TXG) announced its quarterly earnings data on Thursday. The company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.27) by $0.12, FiscalAI reports. The company had revenue of $150.67 million for the quarter, compared to analyst estimates of $147.96 million. 10x Genomics had a negative return on equity of 9.33% and a negative net margin of 12.18%. 10x Genomics’s revenue for the quarter was up 1.1% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.22) EPS.

Here are the key takeaways from 10x Genomics’ conference call:

• Third-quarter revenue was $150.7 million, up 1% year over year, and 10X raised its 2026 revenue outlook to $625 million–$635 million. Excluding patent-litigation settlement revenue, the range implies 4%–6% growth over 2025.
• Atera commercial shipments began in September, and the company now expects to ship about 50 instruments by year-end, up from its prior estimate of 40. Management cited strong demand, while noting that production, installation, and customer training—not orders—are limiting the pace of rollout.
• Spatial consumables revenue grew 16%, with strong Xenium demand; management expects double-digit spatial consumables growth in Q4 as Atera consumables shipments begin. It said customer interest in Atera’s whole-transcriptome option has exceeded expectations.
• Instrument revenue fell 43% as sales of Chromium, Visium, and Xenium instruments declined, partly reflecting customers waiting for Atera. Gross margin was 75% in Q3, but management expects it to fall to the low-to-mid 60% range in Q4 and to be lower in 2027 as Atera placements make the mix more instrument-heavy.
• Single-cell reaction volumes grew at a double-digit rate, supported by Flex Apex adoption, but single-cell consumables revenue rose only 1%. Management said the lower price per reaction for Apex is weighing on revenue as customers shift toward the platform.

10x Genomics Price Performance

Shares of NASDAQ:TXG traded up $1.22 during trading on Friday, reaching $59.28. The stock had a trading volume of 4,522,645 shares, compared to its average volume of 4,178,377. The stock has a market capitalization of $7.72 billion, a PE ratio of -114.00 and a beta of 2.03. 10x Genomics has a 52 week low of $13.58 and a 52 week high of $102.81. The business’s 50-day moving average price is $73.95 and its 200 day moving average price is $41.59.

More 10x Genomics News

Here are the key news stories impacting 10x Genomics this week:

• Positive Sentiment: 10x Genomics reported a Q3 loss of $0.15 per share, narrower than analysts’ expectations, while revenue of $150.7 million topped estimates. The company also raised its 2026 revenue outlook to $625 million–$635 million, above the roughly $620 million consensus. Q3 results
• Positive Sentiment: The company launched Sentira Single Cell, an AI-powered tool intended to simplify cell-data analysis. The product could support research adoption and create recurring revenue opportunities. Sentira launch
• Neutral Sentiment: Citigroup raised its price target from $50 to $60 but kept a neutral rating, suggesting limited upside at the cited share price. Citi target update
• Negative Sentiment: UBS cut its target from $90 to $61 and maintained a neutral rating. Meanwhile, Q3 revenue grew just 1.1% year over year and the company remains loss-making; management also cited production constraints and margin pressure, tempering optimism around stronger Atera demand. UBS target update Q3 call highlights

Insider Buying and Selling at 10x Genomics

In other 10x Genomics news, Director John Stuelpnagel sold 20,000 shares of the business’s stock in a transaction on Thursday, September 3rd. The stock was sold at an average price of $61.75, for a total value of $1,235,000.00. Following the transaction, the director owned 328,436 shares of the company’s stock, valued at approximately $20,280,923. The trade was a 5.74% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Serge Saxonov sold 25,000 shares of the stock in a transaction that occurred on Tuesday, September 22nd. The shares were sold at an average price of $81.22, for a total transaction of $2,030,500.00. Following the sale, the chief executive officer directly owned 1,050,249 shares in the company, valued at $85,301,223.78. This trade represents a 2.33% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 179,333 shares of company stock worth $11,810,070 over the last 90 days. Company insiders own 8.84% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently weighed in on TXG. Citigroup lifted their target price on shares of 10x Genomics from $50.00 to $60.00 and gave the company a “neutral” rating in a research report on Friday. Piper Sandler upped their price target on 10x Genomics from $47.00 to $80.00 and gave the company a “neutral” rating in a research report on Monday, September 28th. UBS Group dropped their price objective on 10x Genomics from $90.00 to $61.00 and set a “neutral” rating for the company in a research note on Friday. TD Cowen lifted their price objective on 10x Genomics from $47.00 to $70.00 and gave the company a “hold” rating in a report on Tuesday, October 13th. Finally, Canaccord Genuity Group boosted their target price on shares of 10x Genomics from $60.00 to $100.00 and gave the company a “buy” rating in a research note on Monday, October 12th. Five investment analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $68.07.

10x Genomics Company Profile

10x Genomics, Inc is a life sciences technology company that develops tools for analyzing biological systems at the single-cell and spatial levels. Its technologies are designed to help researchers study gene expression, cellular interactions, tissue organization and other biological processes in greater detail than conventional laboratory methods.

The company’s product portfolio includes the Chromium platform for single-cell analysis, the Visium platform for spatial transcriptomics, and the Xenium platform for high-resolution in situ analysis of tissue samples.